Therefore, DYRK1A inhibitors have potential as correctors of DS and AD associated sleep problems thereby causing a predicted increase in Aβ42 and Tau clearance, slow pathology and thereby boast cognition8,65. The gene discussed is MAPT; the disease is Alzheimer disease.